Literature DB >> 1135442

Lamb ductus arteriosus: effect of prostaglandin synthesis inhibitors on the muscle tone and the response to prostaglandin E2.

F Coceani, P M Olley, E Bodach.   

Abstract

The prostaglandin synthesis inhibitors, indomethacin and eicosa-5,8,11, 14-tetraynoic acid (ETA), have been tested on the isolated lamb ductus arteriosus at low and high PO2 levels. Both compounds produced a gradual contraction of the hypoxic vessel, and at equal doses the effect of indomethacin was stronger. The maximal tension output of the hypoxic tissue under indomethacin was equal to that of the oxygen-contracted control. ETA- and indomethacin-treated preparations contracted further upon transfer from a low to a high oxygen environment, and the response under indomethacin exceeded a significantly control values. Control preparations were relaxed markedly by PGE2 in low oxygen but showed little or no response in high oxygen. In contrast, preparations pretreated with the inhibitors retained their sensitivity to PGE2 during exposure to high oxygen. The data are consistent with the idea that E-type prostaglandins play a role in the regulation of the intrinsic tone of the ductus arteriosus during foetal life. It is also suggested that the sensitivity of ductal muscle to E-type prostaglandins is controlled by the rate of endogenous prostaglandin formation.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1135442     DOI: 10.1016/0090-6980(75)90034-9

Source DB:  PubMed          Journal:  Prostaglandins        ISSN: 0090-6980


  17 in total

Review 1.  Novel drug targets for ductus arteriosus manipulation: Looking beyond prostaglandins.

Authors:  Elaine L Shelton; Gautam K Singh; Colin G Nichols
Journal:  Semin Perinatol       Date:  2018-05-10       Impact factor: 3.300

2.  Pharmacological manipulation of the ductus arteriosus.

Authors:  E D Silove
Journal:  Arch Dis Child       Date:  1986-09       Impact factor: 3.791

Review 3.  Pharmacologic manipulation of the ductus arteriosus in the neonate: a physiologic basis and current state of the art.

Authors:  S K Sanyal; A Abu-Melha
Journal:  Indian J Pediatr       Date:  1988 Jan-Feb       Impact factor: 1.967

Review 4.  Genetics of the patent ductus arteriosus (PDA) and pharmacogenetics of PDA treatment.

Authors:  Tamorah R Lewis; Elaine L Shelton; Sara L Van Driest; Prince J Kannankeril; Jeff Reese
Journal:  Semin Fetal Neonatal Med       Date:  2018-02-24       Impact factor: 3.926

Review 5.  Patent ductus arteriosus: experimental aspects.

Authors:  J C Mott
Journal:  Arch Dis Child       Date:  1980-02       Impact factor: 3.791

Review 6.  The central control of fetal breathing and skeletal muscle movements.

Authors:  G S Dawes
Journal:  J Physiol       Date:  1984-01       Impact factor: 5.182

7.  Interactions between indomethacin, noradrenaline and vasodilators in the fetal rabbit ductus arteriosus.

Authors:  G C Smith; J C McGrath
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

Review 8.  Pharmacological Closure of Patent Ductus Arteriosus: Selecting the Agent and Route of Administration.

Authors:  Sindhu Sivanandan; Ramesh Agarwal
Journal:  Paediatr Drugs       Date:  2016-04       Impact factor: 3.022

9.  The prostaglandin challenge. Test to unmask obstructed total anomalous pulmonary venous connections in asplenia syndrome.

Authors:  R M Freedom; P M Olley; F Coceani; R D Rowe
Journal:  Br Heart J       Date:  1978-01

10.  Spontaneous Rhythmic Contractions (Vasomotion) of the Isolated, Pressurized Ductus Arteriosus of Preterm, but Not Term, Fetal Mice.

Authors:  Megan Vucovich; Noah Ehinger; Stanley D Poole; Fred S Lamb; Jeff Reese
Journal:  EJ Neonatol Res       Date:  2012-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.